[go: up one dir, main page]

MX2019005999A - Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas. - Google Patents

Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas.

Info

Publication number
MX2019005999A
MX2019005999A MX2019005999A MX2019005999A MX2019005999A MX 2019005999 A MX2019005999 A MX 2019005999A MX 2019005999 A MX2019005999 A MX 2019005999A MX 2019005999 A MX2019005999 A MX 2019005999A MX 2019005999 A MX2019005999 A MX 2019005999A
Authority
MX
Mexico
Prior art keywords
plasma
provides
immunoglobins
precipitation
fraction
Prior art date
Application number
MX2019005999A
Other languages
English (en)
Inventor
Schwarz Hans-Peter
Teschner Wolfgang
Bruckschwaiger Leopold
Gundinger Thomas
Nuernberger Julia
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47833446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005999(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2019005999A publication Critical patent/MX2019005999A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/145Extraction; Separation; Purification by extraction or solubilisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Métodos para elaborar composiciones de proteínas sanguíneas a partir de plasma agrupado. En una modalidad, se provee un esquema de fraccionamiento con alcohol que permite aumentar significativamente el rendimiento de proteínas sanguíneas purificadas a partir de una muestra de plasma de partida. En una modalidad específica se provee un método de fraccionamiento de plasma agrupado que comprende un paso inicial de precipitación con una concentración elevada de alcohol, a pH bajo. También se proveen composiciones farmacéuticas con proteínas sanguíneas terapéuticas.
MX2019005999A 2012-02-23 2014-08-21 Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas. MX2019005999A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261602488P 2012-02-23 2012-02-23

Publications (1)

Publication Number Publication Date
MX2019005999A true MX2019005999A (es) 2019-08-21

Family

ID=47833446

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014010076A MX365236B (es) 2012-02-23 2013-02-25 Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas.
MX2019005999A MX2019005999A (es) 2012-02-23 2014-08-21 Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014010076A MX365236B (es) 2012-02-23 2013-02-25 Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas.

Country Status (25)

Country Link
US (1) US9782477B2 (es)
EP (2) EP4119574A1 (es)
JP (1) JP6291423B2 (es)
KR (1) KR101930582B1 (es)
CN (1) CN104245730B (es)
AR (1) AR090425A1 (es)
AU (1) AU2013203112B2 (es)
BR (1) BR112014020602B1 (es)
CA (1) CA2864715A1 (es)
CL (1) CL2014002225A1 (es)
CO (1) CO7081143A2 (es)
DK (1) DK2817334T3 (es)
EA (1) EA032478B1 (es)
ES (1) ES2928954T3 (es)
HU (1) HUE060195T2 (es)
IL (1) IL234103B (es)
MX (2) MX365236B (es)
MY (1) MY167235A (es)
NZ (1) NZ628529A (es)
PL (1) PL2817334T3 (es)
PT (1) PT2817334T (es)
SG (1) SG11201405149UA (es)
SI (1) SI2817334T1 (es)
TW (1) TWI629283B (es)
WO (1) WO2013126904A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN104004091B (zh) * 2014-06-12 2016-08-17 新疆德源生物工程有限公司 一种人免疫球蛋白的制备工艺
CN104004090A (zh) * 2014-06-12 2014-08-27 新疆德源生物工程有限公司 一种人免疫球蛋白的制备方法
GB201413227D0 (en) 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
US10722535B2 (en) * 2015-08-13 2020-07-28 Kamada Ltd. Compositions derived from Cohn fraction paste and use thereof
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
IL278584B2 (en) * 2018-05-17 2025-08-01 Csl Behring Ag Method and system of protein extraction
US20230002444A1 (en) * 2019-11-20 2023-01-05 Csl Behring Ag Method for extracting a protein from a precipitate and method for precipitating impurities
AU2021355325A1 (en) * 2020-04-10 2022-11-03 Plasma Technologies, Llc Compositions and methods for simplified high efficiency isolation of proteins
CN116322920A (zh) * 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii
CN112250757A (zh) * 2020-11-13 2021-01-22 广东深蓝生物科技有限公司 一种猪血浆中蛋白质的提取纯化方法
EP4271706A4 (en) * 2020-12-28 2025-01-15 Plasma Technologies LLC SYSTEMS AND METHODS FOR THE ISOLATION OF IMMUNGLOBULIN G ON A PROCESS SCALE
CN118580342B (zh) * 2024-05-20 2025-02-07 广东丹霞生物制药有限公司 一种静脉注射用人免疫球蛋白制剂的制备工艺

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (es) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US3998946A (en) 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) * 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
US6284874B1 (en) 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
TW541179B (en) 1997-03-19 2003-07-11 Green Cross Corp Process for preparing immunoglobulin preparation
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
CN1520885A (zh) 1997-10-23 2004-08-18 ������ҩ��ʽ���� 可室温贮存的免疫球蛋白静脉注射制剂
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
WO2003004982A1 (en) * 2001-07-05 2003-01-16 Hamamatsu Photonics K.K. Spectroscopic device
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US7879800B2 (en) 2003-09-22 2011-02-01 Kamada Ltd. Large scale preparation of alpha-1 proteinase inhibitor and use thereof
MXPA06008435A (es) 2004-01-30 2007-05-23 Suomen Punainen Risti Veripalvelu Proceso de manufactura de una inmunoglobulina libre de virus.
ES2407380T5 (es) 2004-02-27 2017-07-07 Octapharma Ag Procedimiento para proporcionar una preparación de anticuerpos purificada, sin riesgo respecto a virus
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
WO2008113589A1 (en) 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
EP2435474A2 (en) * 2009-05-27 2012-04-04 Baxter International Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
US8304524B2 (en) * 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma

Also Published As

Publication number Publication date
KR20140135996A (ko) 2014-11-27
NZ628529A (en) 2016-09-30
JP2015509506A (ja) 2015-03-30
WO2013126904A1 (en) 2013-08-29
TW201348248A (zh) 2013-12-01
IL234103A0 (en) 2014-09-30
AU2013203112A1 (en) 2013-09-12
EP2817334B1 (en) 2022-09-21
EP2817334A1 (en) 2014-12-31
PL2817334T3 (pl) 2022-11-21
SI2817334T1 (sl) 2022-11-30
HK1205520A1 (en) 2015-12-18
ES2928954T3 (es) 2022-11-23
US20130224183A1 (en) 2013-08-29
HUE060195T2 (hu) 2023-02-28
IL234103B (en) 2019-11-28
EA032478B1 (ru) 2019-06-28
AR090425A1 (es) 2014-11-12
TWI629283B (zh) 2018-07-11
CN104245730B (zh) 2017-09-01
US9782477B2 (en) 2017-10-10
BR112014020602B1 (pt) 2022-12-20
CN104245730A (zh) 2014-12-24
SG11201405149UA (en) 2014-09-26
CO7081143A2 (es) 2014-10-10
CL2014002225A1 (es) 2015-01-16
PT2817334T (pt) 2022-10-17
DK2817334T3 (da) 2022-10-03
MX2014010076A (es) 2014-09-22
MX365236B (es) 2019-05-28
KR101930582B1 (ko) 2018-12-18
MY167235A (en) 2018-08-14
CA2864715A1 (en) 2013-08-29
AU2013203112B2 (en) 2016-03-10
EA201491564A1 (ru) 2015-04-30
BR112014020602A2 (pt) 2018-09-11
JP6291423B2 (ja) 2018-03-14
EP4119574A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
MX2019005999A (es) Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas.
EA201390156A1 (ru) ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
EA202090817A1 (ru) Триспецифические белки и способы их применения
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
WO2013060867A3 (en) Production of heterodimeric proteins
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
IN2014KN00929A (es)
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
HK1206636A1 (zh) 用於制备肿瘤相关蛋白和多肽的修饰的多核苷酸
MY168757A (en) Novel compounds as modulators of protein kinases
WO2013177115A3 (en) Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
BR112013032434A2 (pt) restauração dentária, método para sua produção e vidro cerâmico
EA201591229A1 (ru) Способы очистки матричной рнк
EA201391489A1 (ru) Композиции со сниженной вязкостью
WO2013138793A3 (en) Affinity reagants for protein purification
EP3816288A3 (en) Modulation of hepatitis b virus (hbv) expression
EA201591685A1 (ru) Способы и промежуточные соединения для получения лекарственного препарата
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
IN2014DN06164A (es)
EA201300127A1 (ru) Комбинированная фармацевтическая композиция и способ лечения головокружения различного генеза, кинетоза и вегетососудистой дистонии
EA201071316A1 (ru) Иммуномодуляция ингибиторами ингибиторов апоптоза
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
MX2020000288A (es) Cromatografia.
MX2017000014A (es) Metodo para producir acido graso de cadena media con el uso de beta-cetoacil-proteina portadora de acilo (acp) sintasa.